姓名：李念光
职称：教授
E-mail：linianguang@163.com
主要研究方向：血液肿瘤新药物分子发现及优化
个人简介
李念光，教授，博士生导师，现任江苏省药学会药物化学专业委员会委员，南京市药学会药物化学与药物分析专业委员会副主任委员。2011年入选江苏省333人才培养第三层次培养对象，2012年入选“教育部新世纪优秀人才支持计划”，2013年入选江苏省第十批“六大人才高峰”，2013年获教育部霍英东青年教师奖三等奖。近年来主要从事血液肿瘤新药物分子的设计与合成研究，主持10多项国家及省部级项目，在Advanced Science、Journal of Experimental & Clinical Cancer Research、Journal of Medicinal Chemistry、Journal of Chemical Information and Modeling等杂志发表SCI论文100余篇。申请国家发明专利11项，授权9项。指导本科生获大学生“挑战杯”课外学术竞赛国家级二等奖2项，研究生获江苏省优秀毕业论文1次，担任本科教学《药物化学》、《药物合成》以及研究生教学《药物化学专论》、《药物合成化学》课程负责人。
承担的主要科研项目
1. 国家自然科学基金面上项目（82373710），新型构象稳定的大环类FLT3抑制剂的设计、合成与抑制门控卡口氨基酸F691L突变导致的急性髓性白血病耐药活性研究，2024/01-2027/12，主持，49万
2. 国家自然科学基金面上项目（81973171），基于结构的新型选择性FLT3共价抑制剂的设计、合成及其对（复发性及预后不良）急性髓性白血病的生物活性研究，2020/01-2023/12，主持，55万
代表性论文
1. Nian-Guang Li* et al. PNPO-mediated Oxidation of DVL3 Promotes Multiple Myeloma Malignancy and Osteoclastogenesis by Activating the Wnt/β-catenin Pathway. Advanced Science, 2025, 12(5), 2407681. (IF 14.2994)
2. Nian-Guang Li* et al. Design, Synthesis and Biological Evaluation of 3,4-Dihydroisoquinolin-1(2H)-one Derivatives as Protein Arginine Methyltransferase 5 Inhibitors for the Treatment of non-Hodgkin’s Lymphoma. Journal of Medicinal Chemistry, 2025, 68(1), 108-134. (IF 6.7996)
3. Nian-Guang Li* et al. Discovery of SILA-123 as a Highly Potent FLT3 Inhibitor for the Treatment of Acute Myeloid Leukemia with Various FLT3 Mutations. Journal of Medicinal Chemistry, 2024, 67(24), 21752-21780. (IF 6.7996)
4. Nian-Guang Li* et al. The Discovery of 1-(Phenylsulfonyl)-1,2,3,4-tetrahydroquinoline Derivative as Orally Bioavailable and Safe RORγt Inverse Agonist for the Treatment of Rheumatoid Arthritis. Journal of Medicinal Chemistry, 2024, 67(22), 20315-20342. (IF 6.7996)
5. Nian-Guang Li* et al. Discovery of RORγ Allosteric Fluorescent Probes and the Application: Fluorescence Polarization, Screening and Bioimaging. Journal of Medicinal Chemistry, 2024, 67(5), 4194−4224. (IF 6.7996)
6. Nian-Guang Li* et al. Unraveling the Promise of RET Inhibitors in Precision Cancer Therapy by Targeting RET Mutations. Journal of Medicinal Chemistry, 2024, 67(6), 6, 4346-4375. (IF 6.7996)
7. Nian-Guang Li* et al. Medicinal chemistry strategies for the development of Bruton’s tyrosine kinase inhibitors against resistance. Journal of Medicinal Chemistry, 2022, 65, 7415−7437. (IF 6.7996)
8. Nian-Guang Li* et al. Small-molecule Fms-like tyrosine kinase 3 inhibitors: An attractive and efficient method for the treatment of acute myeloid leukemia. Journal of Medicinal Chemistry, 2020, 63(21), 12403−12428. (IF 6.7996)
9. Nian-Guang Li* et al. AHSA1 is a promising therapeutic target for cellular proliferation and proteasome inhibitor resistance in multiple myeloma. Journal of Experimental & Clinical Cancer Research, 2022, 41:11. (IF 11.3997)
10. Nian-Guang Li* et al. Kinase-Bench: Comprehensive Benchmarking Tools and Guidance for Achieving Selectivity in Kinase Drug Discovery. Journal of Chemical Information and Modeling, 2024, 64(24), 9528−9550. (IF 5.5999)
